Real-world studies of crizotinib in patients with ROS1-positive non-small-cell lung cancer: experience from China
Publication: Journal of Comparative Effectiveness Research
Abstract
The treatment of non-small-cell lung cancer (NSCLC) has progressed from histology-oriented cytotoxic therapy to the era of molecular biology-oriented targeted therapy and immunotherapy. As the first tyrosine kinase inhibitor (TKI) targeting the ROS1 pathway, crizotinib is widely used as a first-line regimen for ROS1-rearranged NSCLC. However, due to the paucity of solid data from randomized, controlled phase III clinical studies, clinicians often require more systematic, real-world data-based guidance for its optimal clinical use. As one of the leading countries of real-world research on crizotinib, China has contributed significantly to data on standardization of the therapeutic use of crizotinib, including its clinical treatment patterns, the timing and duration of treatment and drug resistance monitoring and management.
Shareable abstract
A series of real-world studies in China has contributed significantly to standardization of the clinical use of crizotinib. This article summarizes the practical experience of crizotinib in ROS1-positive NSCLC in China, and provides more evidence for clinicians to make optimal clinical decisions.
Plain language summary
As the game-changer for the treatment of advanced ROS1-positive non-small-cell lung cancer (NSCLC), crizotinib is currently one of the most recommended first-line treatment options for these patients. However, as crizotinib was initially approved for the treatment of ALK-positive NSCLC, data from large-scale randomized, controlled trials of crizotinib in ROS1-positive NSCLC patients are limited. Consequently, the availability of comprehensive and large-scale, real-world evidence and clinical practice experience data from China is particularly important for its optimal use. In this review, we summarize the clinical efficacy and safety of crizotinib, drug resistance mechanisms and related mutation patterns and treatment options after drug resistance based on real-world experience in China to help clinicians in this country and elsewhere in the world make clinical decisions.
Formats available
You can view the full content in the following formats:
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Xia C, Dong X, Li H et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin. Med. J. (Engl.) 135(5), 584–590 (2022).
2.
Gendarme S, Bylicki O, Chouaid C, Guisier F. ROS-1 fusions in non-small-cell lung cancer: evidence to date. Curr. Oncol. 29(2), 641–658 (2022).
3.
D'angelo A, Sobhani N, Chapman R et al. Focus on ROS1-positive non-small cell lung cancer (NSCLC): crizotinib, resistance mechanisms and the newer generation of targeted therapies. Cancers (Basel) 12(11), 3293 (2020).
4.
Lin JJ, Shaw AT. Recent advances in targeting ROS1 in lung cancer. J. Thorac. Oncol. 12(11), 1611–1625 (2017).
5.
Huber KV, Salah E, Radic B et al. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature 508(7495), 222–227 (2014).
6.
Lin JJ, Choudhury NJ, Yoda S et al. Spectrum of mechanisms of resistance to crizotinib and lorlatinib in ROS1 fusion-positive lung cancer. Clin. Cancer Res. 27(10), 2899–2909 (2021).
7.
Shaw AT, Ou SH, Bang YJ et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N. Engl. J. Med. 371(21), 1963–1971 (2014).
8.
Shaw AT, Riely GJ, Bang YJ et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann. Oncol. 30(7), 1121–1126 (2019).
•• A pivotal study which showed that targeting ROS1 was an effective treatment strategy in patients with ROS1-rearranged non-small cell lung cancer (NSCLC), leading to approval of crizotinib.
9.
Michels S, Massuti B, Schildhaus HU et al. Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): a European phase II clinical trial. J. Thorac. Oncol. 14(7), 1266–1276 (2019).
10.
Wu YL, Yang JC, Kim DW et al. Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer. J. Clin. Oncol. 36(14), 1405–1411 (2018).
11.
Landi L, Chiari R, Tiseo M et al. Crizotinib in MET-deregulated or ROS1-rearrangedpretreated non–small cell lung cancer (METROS): a phase II, prospective, multicenter, two-arms trial. Clin. Cancer Res. 25, 7312–7319 (2019).
12.
Moro-Sibilot D, Cozic N, Perol M et al. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. Ann. Oncol. 30(12), 1985–1991 (2019).
13.
Zhang Q, Wu C, Ding W et al. Prevalence of ROS1 fusion in Chinese patients with non-small cell lung cancer. Thorac. Cancer 10(1), 47–53 (2019).
14.
Zhuang X, Zhao C, Li J et al. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF. Cancer Med. 8(6), 2858–2866 (2019).
15.
Zhang L, Jiang T, Zhao C et al. Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement. Oncotarget 7(46), 75145–75154 (2016).
• The first large-scale, retrospective study to comprehensively investigate the efficacy of crizotinib and chemotherapy in Chinese patients with ROS1 fusion-positive NSCLC.
16.
Zeng L, Li Y, Xiao L et al. Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer. Onco Targets Ther. 11, 6937–6945 (2018).
•• The first real-world study demonstrating the efficacy of crizotinib in the first-line setting of Chinese ROS1-positive patients with NSCLC.
17.
Li Z, Shen L, Ding D et al. Efficacy of crizotinib among different types of ROS1 fusion partners in patients with ROS1-rearranged non-small cell lung cancer. J. Thorac. Oncol. 13(7), 987–995 (2018).
18.
Liu C, Yu H, Chang J et al. Crizotinib in Chinese patients with ROS1-rearranged advanced non–small-cell lung cancer in routine clinical practice. Target Oncol. 14(3), 315–323 (2019).
19.
Zhu YC, Zhang XG, Lin XP et al. Clinicopathological features and clinical efficacy of crizotinib in Chinese patients with ROS1-positive non-small cell lung cancer. Oncol. Lett. 17(3), 3466–3474 (2019).
20.
Xu H, Zhang Q, Liang L et al. Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants. Cancer Med. 9(10), 3328–3336 (2020).
21.
Shen L, Qiang T, Li Z, Ding D, Yu Y, Lu S. First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer. Cancer Med. 9(10), 3310–3318 (2020).
22.
Zheng J, Cao H, Li Y et al. Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: a multicenter retrospective study. Lung Cancer 147, 130–136 (2020).
23.
Zhang Y, Zhang X, Zhang R et al. Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study. BMC Med. 19(1), 206 (2021).
24.
Zhang Y, Huang Z, Zeng L et al. Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements. NPJ Precis. Oncol. 6(1), 20 (2022).
•• An important study that provides real-world clinical evidence of the association between the molecular mechanisms of resistance and patterns of disease progression in patients with ROS1-rearranged advanced NSCLC who received first-line crizotinib.
25.
Sehgal K, Patell R, Rangachari D, Costa DB. Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors. Transl. Cancer Res. 7(Suppl. 7), S779–S786 (2018).
26.
Gainor JF, Tseng D, Yoda S et al. Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small-cell lung cancer. JCO Precis. Oncol. 2017, PO.17.00063 (2017).
27.
Tremblay G, Groff M, Iadeluca L et al. Effectiveness of crizotinib versus entrectinib in ROS1-positive non-small-cell lung cancer using clinical and real-world data. Future Oncol. 18(17), 2063–2074 (2022).
28.
Shaw AT, Solomon BJ, Chiari R et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase I–II trial. Lancet Oncol. 20(12), 1691–1701 (2019).
29.
Lim SM, Kim HR, Lee JS et al. Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. J. Clin. Oncol. 35(23), 2613–2618 (2017).
30.
Drilon A, Camidge DR, Lin JJ et al. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. N. Engl. J. Med. 390(2), 118–131 (2024).
31.
Li W, Xiong AW, Yang N et al. Efficacy and safety of taletrectinib in Chinese patients with ROS1+ non-small cell lung cancer: the phase II TRUST-I study. J. Clin. Oncol. 42(22), 2660–2670 (2024).
32.
Liu Z, Zhao K, Wei S et al. ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer. Oncoimmunology 9(1), 1758003 (2020).
33.
Cai L, Duan J, Qian L et al. ROS1 fusion mediates immunogenicity by upregulation of PD-L1 after the activation of ROS1-SHP2 signaling pathway in non-small cell lung cancer. Front Immunol. 11, 527750 (2020).
Information & Authors
Information
Published In
Copyright
© 2024 The Authors. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 22 March 2024
Accepted: 3 December 2024
Published online: 17 December 2024
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Real-world studies of crizotinib in patients with ROS1-positive non-small-cell lung cancer: experience from China. (2024) Journal of Comparative Effectiveness Research. DOI: 10.57264/cer-2024-0043
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Hai-Long Zhang, Yongxia Li, Deep learning-based dual/triple-target prediction models for KRAS G12C/D and EGFR/ROS1/ALK inhibitors, In Silico Research in Biomedicine, 10.1016/j.insi.2026.100382, 2, (100382), (2026).
- Mengli Qiu, Peiwen Guo, Sisi Wang, Yong Zhu, Siqi Wu, Huiting Peng, Zehuai Guo, Yanmeng Guo, Jieheng Lin, Yang Cao, Case report: Durable response of immuno-chemotherapy targeting a rare ROS1 fusion-positive extensive-stage SCLC patient after primary resistance to crizotinib, Frontiers in Pharmacology, 10.3389/fphar.2025.1522542, 16, (2025).
- Alper Topal, Goncagul Akdag, Sedat Yildirim, Oguzcan Kinikoglu, Deniz Isik, Gizem Yildirim, Salih Tunbekici, Fatih Kus, Aydın Acarbay, Murad Guliyev, Nargiz Majidova, Yasin Kutlu, Mustafa Erman, Hatice Odabas, Nedim Turan, Nuri Karadurmus, Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study, Medicina, 10.3390/medicina61030490, 61, 3, (490), (2025).